https://bms-540215inhibitor.co....m/device-mastering-e
Early development following the first-line R-CHOP treatment contributes to a rather dismal result and necessitates alternative treatment for patients with diffuse large B-cell lymphoma (DLBCL). This research aimed to develop a genetic predictive model for early progression and assess its prospective in advancing alternative treatment. Thirty-two hotspot driver genes were analyzed in 145 DLBCL patients and 5 DLBCL cell lines utilizing next-generation sequencing. The organization of clinical functions, c
Like
Comment
Share
